Reprints will not be available Word count: Paper: 3497 words. Abstract: 150 words 2 ABSTRACT Objective: To determine whether outcomes differed for pre-eclamptic (PE) women according to the presence of proteinuria and whether non-proteinuric PE is similar to gestational hypertension (GH). From 1987From -2005, at three hospitals in Sydney, Australia, women referred to the obstetric medicine team were recruited. Outcomes for three groups were compared -proteinuric PE, non-proteinuric PE and GH.
INTRODUCTION
Hypertensive disorders in pregnancy are common, affecting around 10-12% of pregnant women. About 3-4% have pre-eclampsia (PE), a similar proportion has gestational hypertension (GH) and 1-2% has pre-existing chronic hypertension. [1] There is a lack of data available on the outcomes of hypertensive pregnancies, particularly for women with a consistent diagnosis of gestational hypertension compared with pre-eclampsia. Population-based research in Australia [2] [3] [4] has relied on data sets that are known to suffer from under-reporting and misclassification of gestational hypertension and pre-eclampsia [5, 6] .
Since 1987, we have maintained a prospective database of all women who were referred to two obstetric medicine physicians, either during pregnancy or in the immediate postpartum period. To date, women having 3,345 pregnancies have received this care. This study builds on a previous analysis of this database that was published in 1996 [1] .
In this study, we used a consistent diagnostic approach with each woman classified by one of two physicians. The hospitals involved used a single uniform management policy. The aim of the study was to determine 1) whether outcomes differed within pre-eclamptic women according to the presence or absence of proteinuria, using the International Society for the Study of Hypertension in Pregnancy (ISSHP) classification system [7] and 2) whether non-proteinuric pre-eclampsia was similar to gestational hypertension.
5

MATERIALS AND METHODS
Classification of hypertension in pregnancy
Several groups have developed classification schemes in an attempt to produce consistency in clinical practice and research [8] [9] [10] [11] [12] [13] [14] .
Unfortunately, the classifications systems differ making comparisons across studies difficult [15] .
The definitions used in this study are:
Gestational Hypertension (GH): average SBP ≥ 140mmHg and/or DBP ≥ 90mmHg (phase 5) (after overnight rest in hospital, or after completion of a day assessment visit), developing after 20 weeks gestation, without any evidence of multi-system dysfunction (eg. kidneys, brain, liver, clotting). Indications for referral were:
Preeclampsia (PE)
• Hypertension failing to settle after overnight rest in hospital or repeated high measures in a day-only unit;
• The presence of proteinuria, neurological factors, abnormal biochemistry (elevated serum transaminase or creatinine levels) or thrombocytopenia;
• Recurrent admissions for hypertension; or
• A suspected secondary cause for hypertension.
There were no specific exclusion criteria but it is possible that women with very mild or transient gestational hypertension may not have been referred to this service.
Setting
The study took place in three hospitals in southern Sydney. One was a public referral centre, the others were private hospitals. The public hospital is a teaching hospital without a neonatal intensive care unit or a dedicated specialist maternal-fetal medicine unit, delivering approximately 2400 babies per year. Women whose babies are likely to be born prior to 32 weeks gestation are usually transferred to a tertiary centre with these additional services. Outcomes were still recorded for these mothers and babies.
The same obstetricians and physicians practice at the two private hospitals as the public hospital using the same management protocol. The private hospitals together deliver approximately 2700 women per year, making around 5000 births per year [17] .
Once women were referred, the renal physicians, an obstetrician and a midwife managed them as a team. Since 1998, referred women at the public referral hospital were enrolled into the Risk Associated Pregnancy (RAP) Team which incorporated the two physicians, an obstetrician and a group of midwives who were particularly trained and committed to caring for pregnant women with hypertension.
The management of these pregnant women was overseen by two physicians and two obstetricians. The units were guided by consistent and strictly adhered to protocols that guided the measurement of blood pressure, the management of hypertension and episodes of severe hypertension, the use of antihypertensive agents and the optimum time for delivery. The protocols have standardised the management of women across the three sites (available at http://web.med.unsw.edu.au/stgrenal/HT_Pregnancy.htm).
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Classification
The definitions, classifications and complications of hypertension in pregnancy used in the study were those of the ISSHP [7] as described above. Pre-eclampsia differs from eclampsia in that the latter has convulsions as part of its definition. This is an uncommon event in developed countries with good antenatal care and for this reason eclampsia is included within the classification "pre-eclampsia". The definition of proteinuria was a spot urine protein/creatinine ratio (≥ 30mg protein per mmol creatinine) [18] used for the past eight years, and ≥ 300mg per day in the years before this. Dipstick urine was rarely relied upon to make the diagnosis of proteinuria, if so a definition of consistently ≥ '2+' (1g/L) dipstick proteinuria was used [19] . Severe hypertension was defined as ≥ 170 mmHg systolic and/or ≥ 110 mmHg diastolic. The classification was made after delivery hence accounting for women who progressed from GH to PE. Non-proteinuric PE was defined as meeting the clinical criteria for PE without proteinuria.
Women who had thrombocytopenia (<150 x 10 9 L) were retained in the GH group only if they had thrombocytopenia prior to the onset of hypertension as this was thought to be due to Thrombocytopenia of Pregnancy. Small for gestational age was defined as <10th percentile and was not a criteria for PE.
Data collection
Data were collected on each woman in the study at the time of referral and after the birth by the staff involved in the care and management. This data sheet was collected by the attending physicians at the time of discharge from hospital. The final hypertensive diagnosis was made by one of the two attending physicians and recorded on this data sheet. The data sheet was forwarded to a research midwife who collected 9 additional data from the woman's medical records at the three hospitals. Data for women or babies who were transferred to other hospitals were collected from these centres. Data were entered into a MS Access © database by a research midwife.
The maternal biochemical and hematological data used in the analysis were those closest to delivery and always recorded in the seven days prior to the birth of the baby. Complications were those which occurred any time between presentation and discharge from hospital.
Analysis
Data were converted from the MS Access © database into SPSS for statistical analysis.
The primary diagnoses for the whole database were: gestational hypertension; preeclampsia; chronic hypertension and superimposed pre-eclampsia; essential hypertension; renal or other conditions; and, white-coat hypertension. It is acknowledged that white-coat hypertension was under-reported because this diagnosis was not included in this database until 2005 [20] .The analysis in this report is confined to women with a diagnosis of pre-eclampsia or gestational hypertension.
A univariate analysis was initially performed followed by a multivariate analysis for the non-proteinuric versus GH analysis. A P < 0.05 was taken as an alpha level of statistical significance.
In light of recent evidence that uric acid may have a role in vascular dysfunction [21] , the effect of hyperuricemia (UAC > 0.35mmol/L) was examined in more detail in the three groups (proteinuric PE, non-proteinuric PE and GH) on two primary neonatal outcomes: prematurity and small for gestational age. Recent research has suggested that women with GH and hyperuricemia had fetal outcomes similar to that of PE and that within PE there were different outcomes according to hyperuricemia [21] . Odds ratios and 95% confidence intervals were calculated for these final comparisons. The outcomes of women with PE (n=1348) were examined, comparing proteinuric versus non-proteinuric PE. Of this group, 958 (71%) women had proteinuria and 357 (26%) had no proteinuria. In 33 (3%) of cases there was uncertainty so they were excluded from the analysis.
RESULTS
During the period
There were no significant differences between these subsets of pre-eclamptic women in terms of age (30 years in both groups), primiparity (71% vs 67%, p=0. In a multivariate analysis that controlled for parity, women with proteinuric PE were still significantly more likely to have severe hypertension, deliver preterm infants and have a higher perinatal mortality rate while those with non-proteinuric PE were significantly more likely to have thrombocytopenia and liver disease ( Table 2 ).
The outcomes of women with non-proteinuric PE (n=356) were compared with those with gestational hypertension (n=1192). There were no significant differences in:
gestation at booking visit (13 vs 14wks, p=0. There were significant differences in the complications of renal insufficiency, thrombocytopaenia, liver disease and neurological involvement as these are inherent in the definition associated with a diagnosis of non-proteinuric PE (Table 3) .
In a multivariate analysis that controlled for parity, women with non-proteinuric PE were significantly more likely to have a multiple pregnancy, experience severe hypertension and deliver preterm infants who were small for gestation age than those with GH, although the perinatal mortality rate was no different (Table 4) .
Hyperuricemia was associated with a statistically significant higher rate of preterm birth in women with proteinuric PE (Table 5) . Hyperuricemia in women with proteinuric PE was associated with increased odds of having a preterm birth (45% vs 28%, p<0.001; OR 2.1, 95% CI 1.6-2.8) but not increased odds of having a small for gestational age baby (22% vs 17%, p=0.9; OR 1.3, 95% CI 0.9-1.9). In women with GH, hyperuricemia was associated with increased odds of being born small for gestational age (15% vs 10%, p=0.01; OR 1.62, 95% CI 1.11-2.36). No other statistically significant differences were seen between the groups in relation to these selected outcomes (preterm birth, SGA, perinatal mortality) and hyperuricemia.
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DISCUSSION
The key findings of this study are that: 1) women with clinical features of preeclampsia that includes proteinuria have a worse pregnancy outcome, in particular greater perinatal mortality, than those without proteinuria, and 2) women with clinical features of pre-eclampsia without proteinuria have worse pregnancy outcomes, including more prematurity and small for gestational age babies, than women whose only maternal problem is de novo hypertension (gestational hypertension). Whilst the first observation is not new the latter is one which should provoke new thinking about the way we currently classify women with hypertension in pregnancy.
Any classification system is useful only if it helps discriminate groups of hypertensive pregnant women with practical, clinical and/or research utility. Previous researchers have recommended that efforts should be made to recognise different subsets of women with pre-eclampsia and to examine them separately for both outcome and pathophysiologic features [22] [23] [24] . While there is debate about whether proteinuria should remain a 'sine qua non' for the clinical diagnosis of pre-eclampsia [25] proteinuria remains a hallmark of the disorder, an easily measurable clinical tool and a requirement for a research diagnosis of PE [7] . This study examined the outcomes of women with PE depending on whether they had proteinuria or not according to the ISSHP classifications and has highlighted the clinically different implications between making a diagnosis of pre-eclampsia or gestational hypertension.
Women with proteinuric PE experienced more adverse outcomes than those with nonproteinuric PE, particularly preterm birth and perinatal deaths. This supports a classification system that divides pre eclamptic women into those with or without proteinuria [26] .
In contrast, and probably by definition, women with non-proteinuric PE have more organ dysfunction, such as hepatic and platelet complications, than those with proteinuric PE. While this finding is, in part, due to the classification system per se, it is also evident that it defines a group of women with potentially serious problems. It is worth emphasizing that in this analysis any one or more features of such organ dysfunction defined a group of women at greater risk of developing severe hypertension or other adverse outcomes than those without any of these features. The occurrence of liver dysfunction and renal impairment was not coincident enough to draw any analogies between pre-eclampsia and other vasoconstrictive disorders such as the hepato-renal syndrome.
Proteinuria in combination with hypertension has long been considered predictive of increased adverse outcomes for mothers and babies [27, 28] . Women with proteinuric pre-eclampsia have poorer outcomes than those with gestational hypertension (nonproteinuric) alone [29] . However, it appears that the presence or absence of proteinuria is more important than the amount excreted. Research examining the effect of differing levels of proteinuria (5-9.9g/24hr) has suggested that women with pre-eclampsia and high levels of proteinuria did not have higher rates of maternal morbidity than those with lower levels of proteinuria. Neonates whose mothers had very high levels of proteinuria were delivered at an earlier gestational age than women with lower but still significant levels of proteinuria (<5g/24hr) and had more neonatal complications related to prematurity [30] . These authors suggested that the increased adverse perinatal outcomes for babies were associated with the degree of prematurity rather than the proteinuria level.
Research on some of the same cohort as presented in this study examined whether a discriminant value of proteinuria in 321 women with proteinuric pre-eclampsia predicted adverse maternal and fetal outcomes [25] . We demonstrated that there was an increased risk of adverse maternal and fetal outcomes with increasing proteinuria, however, it was not possible to define a level of proteinuria (using the spot protein/creatinine ratio) that could be used as a definitive discriminant value for adverse outcomes. Of interest, these increased maternal and fetal risks became significant in women over 35 years at a protein excretion of roughly 5g per day, similar to the study by Newman et al [30] .
There is general clinical acceptance that proteinuric pre-eclampsia is a real and significant entity. What diagnosis then, do we give to hypertensive pregnant women with organ dysfunction e.g. liver disease, renal insufficiency, who do not have proteinuria? To address this question we examined outcomes between this group i.e.
'non-proteinuric PE' and those with gestational hypertension. By definition the former group had to have higher maternal morbidity but we questioned whether any fetal, perinatal or severe hypertension differences might exist.
Our findings were significant in that women with non-proteinuric pre-eclampsia were more likely to have babies who are preterm and small for gestational age and were 4-5 times more likely to have episodes of severe hypertension. The failure to demonstrate a difference in perinatal death rate between these groups may reflect a type II error.
There were only 353 women in the non-proteinuric pre-eclampsia group and 1200 in the gestational hypertension group. Given the perinatal mortality rate (PNM) rate in both these groups was low, it is likely that a larger sample would be required to demonstrate a difference.
Our data show that even though 'non-proteinuric pre-eclampsia' has significant implications for mother and baby we can reassure these women and those with gestational hypertension that perinatal survival rates are as good as for the overall pregnant population. The perinatal mortality rate for women with GH was 7.5 per 1000 births, lower than the overall perinatal mortality rate in the state of New South Wales, Australia, from 1998-2003 which has varied from 8.6 to 9.6 per 1,000 births [17] . This overall rate includes high and low risk women so it might be expected to be higher than the rate just in women with GH. The perinatal mortality rate in normotensive women in a South Australian cohort was 6.9-8.0 per 1000 which suggests that the PNM rate in women with GH (7.5) is similar to that of normotensive women. Nevertheless, the fact that fetal growth restriction was greater in women with 'non-proteinuric PE' highlights that this is not really the same disorder as the very benign condition of gestational hypertension and it is inappropriate to consider these conditions as one. In addition, this cohort of women with GH was managed by an experienced team using a standard protocol and frequent follow up. It is possible that their favourable outcome was either due to a benign natural history or related to the standard protocol and system of care.
A fundamental question becomes whether proteinuric pre-eclampsia, 'non-proteinuric pre-eclampsia' and gestational hypertension are part of a pathophysiological spectrum or separate disorders. The first two share the same clinical features except a measured protein excretion of greater than 300mg/day. It is possible that intact immunoreactive albumin excretion rates are abnormal in women with 'non-proteinuric' pre-eclampsia or that protein fragment or non-immune albumin excretion is abnormal. To the best of our knowledge such studies have not been done so far. In light of the long standing measurement of uric acid in pre-eclampsia and the recent recognition that this may be involved in vascular reactivity we examined whether outcomes might have differed within groups according to uric acid levels, perhaps to give clues to a pathologic role for uric acid rather than it being a 'bystander' marker of disease due to renal urate retention. We found that women with non-proteinuric PE were slightly but significantly more likely to have hyperuricemia compared with those with proteinuric PE (67% vs 61%,) or GH (42%). Within the proteinuric PE group, hyperuricemia was associated with increased odds of having a preterm birth. This cannot be explained by an increased propensity to induce labour in this group once an increased uric acid was detected as this has never been an indication for delivery in these hospitals; further, the incidence of hyperuricaemia was slightly greater in women with 'non-proteinuric pre-eclampsia' yet no difference in any fetal or other outcome was apparent according to the presence or absence of hyperuricemia. Within the GH group, hyperuricemia was associated with increased odds of having a small for gestational age baby.
Therefore, both women with GH and those with PE had slightly different fetal outcomes according to hyperuricemia consistent with one recent study [21] . We can interpret this as pre-eclampsia being a useful clinical marker of fetal outcome in these groups but this finding gives us little further insight into potential pathophysiologic differences between the various hypertensive disorders of pregnancy.
There are some potential limitations of our study, including the potential for selection bias, quality of the classifications, consistency of management and potential for under-estimation of adverse outcomes. The potential for selection bias arises, as some women who had hypertension in pregnancy may have not been included into the database if they did not require significant management and therefore were not referred. This likelihood is low as referral to the physicians is an accepted part of clinical management in these hospitals.
The risk of poor consistency of clinical management or inaccurate classification is also very small. During this 18-year period, classification and management of hypertension has changed, as have facilities available for neonatal resuscitation and care. The classifications and management used throughout the study period have accounted for these changes and have consistently remained in line with Australian and international systems and evidence [7, 8] . The management of hypertension has been directed by the same two physicians throughout this time period and has been uniform and driven by standard protocols.
Finally, as our three hospitals have no neonatal intensive care unit we do not receive referrals for very preterm babies; 90% of our women were ≥ 34 weeks at delivery and adverse events in babies born earlier may be underestimated giving rise to type II errors even though outcome data from all these women were included in the analysis.
Birth at less than 34 weeks gestation is known to be associated with a higher perinatal mortality and morbidity rate (30) (31) .
CONCLUSION
The study has examined whether pre-eclampsia should be routinely diagnosed and classified as 'proteinuric' or 'non-proteinuric', and whether the latter diagnosis is in any way different for mother and baby than a diagnosis of 'gestational hypertension'.
We have shown clearly that 'non-proteinuric PE' has poorer outcomes for women and their babies than does 'gestational hypertension' but is a more benign condition than proteinuric PE. It is clear that non-proteinuric PE is not the same condition as GH. On the basis of this evidence, we suggest that 'non-proteinuric PE' is a useful subclassification of pre-eclampsia that should be added to existing classification systems to alert clinicians to potential maternal and fetal risks. It is evident that GH has a good prognosis provided these women are carefully observed to exclude those who change from GH to PE [33] . Accordingly, we propose a classification of hypertensive disorders in pregnancy that stratifies maternal and fetal risks more than present classification systems ( Figure 1 ).
We propose that this potential classification system be tested in a new cohort of patients as a system that significantly discriminates maternal and fetal risks in routine clinical practice. 
